The 18 most recent market catalysts affecting $BLCO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 2, 2026
Corporate Catalyst
Bullish
Impact 60
HC Wainwright Downgrades Bausch + Lomb to Neutral from Buy
HC Wainwright & Co. downgraded Bausch + Lomb's stock rating from Buy to Neutral on November 2, 2026. This indicates a more cautious stance from the analyst firm regarding the compa…
Oct 30, 2026
Corporate Catalyst
Neutral
Impact 65
FactSet Analyst Survey Updates Bausch + Lomb EPS Forecast and Price Target
A FactSet survey updated Bausch + Lomb's 2026 EPS estimate upward to $0.94 from $0.80, based on input from 14 analysts. This revision, coupled with a new consensus price target of …
Oct 29, 2026
Corporate Catalyst
Bullish
Impact 75
Analysts Raise Price Targets for Bausch + Lomb Following Q3 Earnings
Bausch + Lomb reported robust third-quarter 2026 financial results, with an 89% year-over-year increase in adjusted net earnings per share, significantly exceeding market expectati…
Oct 28, 2026
Corporate Catalyst
Bullish
Impact 75
Bausch + Lomb Reports Third-Quarter 2026 Financial Results and Raises Full-Year Guidance
Bausch + Lomb announced robust third-quarter 2026 financial results, demonstrating growth across its core business segments and an expansion in profitability. This positive perform…
Oct 19, 2026
Corporate Catalyst
Neutral
Impact 75
Billionaire Investor Took a Stake in Bausch + Lomb Before Its CEO Shake-Up
Dan Loeb's Third Point opening a position in Bausch + Lomb (BLCO) before the CEO change and positive guidance updates is a significant signal. It suggests a belief in the company's…
Oct 12, 2026
Corporate Catalyst
Bearish
Impact 75
Why Is Bausch + Lomb Stock Falling Monday?
Bausch + Lomb (BLCO) announced the immediate departure of CEO Brent Saunders, replaced by interim CEO Thomas J. Appio, who also leads parent company Bausch Health (BHC). This unexp…
Oct 12, 2026
Corporate Catalyst
Bearish
Impact 75
Bausch + Lomb shares are trading lower. The company announced the appointment of Chairman Thomas Appio as interim CEO following Brent Saunders' departure, while also indicating it expects to raise full-year 2026 adjusted EBITDA guidance.
The immediate negative reaction to Bausch + Lomb's stock is primarily due to the uncertainty surrounding the CEO transition. While an interim appointment can stabilize leadership, …
Oct 6, 2026
Corporate Catalyst
Bullish
Impact 75
Bausch + Lomb Says FDA Supportive In Principle Of Initial Study Design For Oral Dry AMD Drug BL1243, Expects 2027 Start
The FDA's 'supportive in principle' stance for the initial study design of BL1243 is a crucial de-risking event for Bausch + Lomb. This positive feedback increases the probability …
Sep 15, 2026
Corporate Catalyst
Bearish
Impact 75
Bausch + Lomb Receives FDA Warning Letter Over Sterile Drug Manufacturing At Tampa Plant, Citing Inadequate Aseptic Controls And Persistent Microbial Contamination; Products Deemed Adulterated
Bausch + Lomb received a Warning Letter from the FDA for its Tampa, Florida sterile drug manufacturing facility, citing significant violations including inadequate aseptic controls…
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 55
Leerink Partners Initiates Coverage On Bausch & Lomb with Outperform Rating, Announces Price Target of $24
Leerink Partners, through analyst Daniel Clark, has initiated coverage on Bausch & Lomb (BLCO) with an 'Outperform' rating and a $24 price target. This event is significant because…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 75
Bausch + Lomb Advances Two Eye Therapies With Blockbuster Sales Potential
Bausch + Lomb announced the progression of two key ophthalmic therapies into advanced clinical testing. The dry eye combination therapy, despite missing its Day 29 primary endpoint…
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 85
Bausch + Lomb Says Dual-Action Dry Eye Drop Missed Phase 2 Primary Endpoint At Day 29, Met Secondary Endpoint At Day 15; Advancing To Phase 3 With Day 15 Primary Endpoint
The headline signals a significant event for Bausch + Lomb (BLCO) as its dry eye drug, a potential blockbuster, experienced a mixed Phase 2 outcome. Missing the Day 29 primary endp…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Bausch & Lomb, Raises Price Target to $21
HC Wainwright & Co. analyst Yi Chen maintained a 'Buy' rating on Bausch & Lomb (BLCO) and raised the price target from $20 to $21. This action indicates a continued bullish outlook…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 55
UBS Maintains Buy on Bausch & Lomb, Raises Price Target to $23
UBS analyst Patrick Wood maintained a 'Buy' rating on Bausch & Lomb and raised the price target from $21 to $23. This action signals continued confidence in the company's future pe…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 92
Bausch & Lomb Q2 Adj. EPS $0.16 Beats $0.15 Estimate, Sales $1.394B Beat $1.369B Estimate
Bausch & Lomb (BLCO) announced Q2 adjusted EPS of $0.16, beating the $0.15 consensus by 6.67%, and sales of $1.394 billion, surpassing the $1.369 billion estimate by 1.84%. This st…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 75
Bausch & Lomb Raises FY2026 Sales Guidance from $5.420B-$5.520B to $5.440B-$5.540B vs $5.468B Est
Bausch & Lomb (BLCO) has updated its fiscal year 2026 sales guidance, raising the lower and upper bounds by $20 million each. This revision moves the new range to $5.440 billion-$5…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 75
Bausch & Lomb Q2 Adj. EPS $0.16, Inline, Sales $1.394B Beat $1.368B Estimate
Bausch & Lomb's Q2 results show a positive trend with sales beating estimates and a substantial year-over-year increase in both EPS and sales. This indicates healthy demand for the…
Jul 28, 2026
Corporate Catalyst
Neutral
Impact 65
UBS Initiates Coverage On Bausch & Lomb with Buy Rating, Announces Price Target of $21
UBS analyst Patrick Wood initiated coverage on Bausch & Lomb (BLCO) with a 'Buy' rating and a $21 price target. This is a positive development for BLCO as new analyst coverage, esp…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.